Nanjing Nuoyuan Medical Devices Co., Ltd.

What the record says.

Fields marked verified by platform were
checked by the B2B platform; self-reported are the
supplier’s own filings. Nothing here is our assessment.

An audit on file.

This record carries a third-party audit report number — CTI QIP-ASI254198 — as published on its source listing.

Verify this report →

The company describes itself.

(hereinafter referred to as Nuoyuan Medical or the Company) was founded in 2011. It stands as a nationally recognized high-tech enterprise, renowned for its profound innovative capabilities, which encompass the entire spectrum of research and development, production, and marketing of cutting-edge medical devices and pioneering targeted contrast agent drugs. The company's core mission revolves around furnishing comprehensive solutions for the precision diagnosis and treatment of cancer, with a special focus on pivotal technologies such as Molecular Fluorescence, Raman Spectroscopy, Artificial Intelligence, Computer-Aided Drug Design (CADD), and AI-facilitated drug design. As a testament to its commitment to innovation, Nuoyuan Medical boasts an extensive product pipeline. Securing authoritative recognition for scientific research and innovation prowess From the very inception of Nuoyuan Medical, it has garnered significant esteem from both the national and Jiangsu provincial governments. The company boasts a portfolio of 79 domestic and international invention patents that span the entire device and its core components. Competitive advantages of Core products Nuoyuan Medical continues to explore minimally invasive and precise treatment solutions, integrating exclusive microwave ablation simulation technology, conformal tumor ablation technology, and carbonization regulation technology to effectively solve clinical problems in tumor microwave treatment and achieve precise ablation. Nuoyuan Medical focuses on the development of artificial intelligence medical device products. The artificial intelligence assisted Automatic Digital Pathological Analysis and Scanning System (ADPASS) developed by Nuoyuan Medical has a high-negative pathological samples discriminating rate, significantly improving the efficiency and accuracy of the diagnosis process. Domestic and International simultaneous market spreading Nuoyuan Medical is in line with the Healthy China strategy and has developed a series of products that have been used in over 500 large hospitals across the country. At the same time, Nuoyuan Medical is a strategic partner of international leading companies such as B. Braun Melsungen, whose multiple products are Originally Designed and Manufactured by Nuoyuan Medical. Nuoyuan Medical is simultaneously promoting the registration of its products in China, the United States and Europe. Until now the company has completed multiple system certifications such as 13485/9001, and multiple products are currently undergoing FDA registration in the United States and CE certification in the European Union. And looking forward to enter the global market. The innovative model of "combining pharmaceuticals and devices" Nuoyuan Medical has utilized its deep accumulation in drug research and development to develop an internationally first-class broad-spectrum fluorescent contrast agent "Indocyanine green". At the same time, AI assisted and CADD technology have been applied to develop multiple novel targeting fluorescent contrast agents for multiple typical tumor markers. Among them, the new generation of targeted "Pemefolacianine" fluorescent contrast agents have high specificity compared to similar fluorescent contrast agents in the United States, and can significantly reduce the false positive rate. This will significantly improve the accuracy of tumor surgical resection, thereby improving the prognosis and patients' life quality. At present, the "Pemefolacianine" fluorescent contrast agent has been granted international invention patents, in China, the United States, Europe, and Japan. View All General Information 8 items verified by CTI Business Type: Manufacturer/Factory & Trading Company Main Products: Endoscope, Indocyanine Green, 2CMOS Camera, 3D4K Fluorescence Endoscope, 2D4K Fluorescence Endoscope, Automatic Pathology Digital Lmaging and Analysis, Sterile Microwave Ablation Needle, Surgical Fluorescence Lmaging System, Camera System, Microwave Ablation System Year of Establishment: 2011-04-11 Number of Employees: 180 Management System Certification: ISO9001:2015, Others Product Certification: CE Repeat Buyers Choice: 80%~100% Address: Nanjing, Jiangsu, China Plant Area: 6928.07 square meters Registered Capital: 34,744,220 RMB Trade Capacity All information verified by CTI Main Markets: Domestic Number of Foreign Trading Staff: 3 Supply Chain Partners: 355 Minimum Order Quantity: 1 Set International Commercial Terms(Incoterms): EXW, FOB Terms of Payment: T/T, LC, D/P, PayPal, Western Union, Small-amount payment Average Lead Time: Peak Season Lead Time: one month Off Season Lead Time: one month Overseas Agent/Branch: No Export Year: 5 Years Nearest Port: Shanghai Port Production Capacity All information verified by CTI Production Lines: 5 Inspection Type for Finished Products: 100% inspection(Visual inspection & Function inspection) Inspection Method for Finished Products: Have instructions and uniformly followed QA/QC Inspectors: 15 people Traceability of Raw Materials: Yes R&D Capacity All information verified by CTI Own Brand: Yes ODM Service Available: Yes OEM Service Available: Yes R&D Engineers: 31 people New Products Launched in Last Year: Yes Customization Options: Full Customization Production Machines: Automatic Assembly Production Line, Assembly Line, Production Assembly Workshop, Constant Temperature and Humidity Aging Test Chamber Company Show

Where it is.

Nanjing, Jiangsu, China.

• Jiangsu
• Nanjing